Cargando…

An overview of kinase downregulators and recent advances in discovery approaches

Since the clinical approval of imatinib, the discovery of protein kinase downregulators entered a prosperous age. However, challenges still exist in the discovery of kinase downregulator drugs, such as the high failure rate during development, side effects, and drug-resistance problems. With the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Beilei, Wu, Hong, Hu, Chen, Wang, Haizhen, Liu, Jing, Wang, Wenchao, Liu, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685278/ https://www.ncbi.nlm.nih.gov/pubmed/34924565 http://dx.doi.org/10.1038/s41392-021-00826-7

Ejemplares similares

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus
por: Wang, Junjie, et al.
Publicado: (2023)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
por: Mei, Husheng, et al.
Publicado: (2023)

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
por: Yu, Kailin, et al.
Publicado: (2017)

Recent Strategic Advances in CFTR Drug Discovery: An Overview
por: Rusnati, Marco, et al.
Publicado: (2020)

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
por: Hu, Chen, et al.
Publicado: (2022)

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
por: Zhao, Zheng, et al.
Publicado: (2014)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
por: Liu, Feiyang, et al.
Publicado: (2016)

Recent Advances in Kinase Drug Discovery Part I: The Editors’ Take
por: Tucker, Julie A., et al.
Publicado: (2021)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

An overview of surgery-first approach: Recent advances in orthognathic surgery
por: Sharma, Vipul Kumar, et al.
Publicado: (2015)

Recent Advances in Histidine Kinase-Targeted Antimicrobial Agents
por: Chen, Hongtong, et al.
Publicado: (2022)

Overview of neurosarcoidosis: recent advances
por: Hebel, Renata, et al.
Publicado: (2014)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Recent Advances in W-Containing Refractory High-Entropy Alloys—An Overview
por: Chen, Shunhua, et al.
Publicado: (2022)

Recent advances and effective strategies in the discovery and applications of natural products
por: Xie, Jing, et al.
Publicado: (2018)

Radical chemistry in polymer science: an overview and recent advances
por: Wang, Zixiao, et al.
Publicado: (2023)

Recent advances in combinatorial biosynthesis for drug discovery
por: Sun, Huihua, et al.
Publicado: (2015)

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Recent Advances in Proteomics and Cancer Biomarker Discovery
por: Xiao, Gary Guishan, et al.
Publicado: (2008)

Overview of Recent Advances in Nano-Based Ocular Drug Delivery
por: Liu, Li-Ching, et al.
Publicado: (2023)

Recent Advances in the Discovery and Development of Marine Microbial Natural Products
por: Xiong, Zhi-Qiang, et al.
Publicado: (2013)

Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy
por: Gao, Ang, et al.
Publicado: (2019)

Recent Advances in Aptamer Discovery and Applications
por: Zhang, Yang, et al.
Publicado: (2019)

Recent advances in phenotypic drug discovery
por: Swinney, David C., et al.
Publicado: (2020)

Recent Advances in Covalent Drug Discovery
por: Schaefer, Daniel, et al.
Publicado: (2023)

Some Recent Advances in Energetic Variational Approaches
por: Wang, Yiwei, et al.
Publicado: (2022)

miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT
por: Liu, Nianli, et al.
Publicado: (2014)

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma
por: Liu, Juan, et al.
Publicado: (2020)

Recent advances in the developmental origin of neuroblastoma: an overview
por: Ponzoni, Mirco, et al.
Publicado: (2022)

Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
por: Shim, Joong Sup, et al.
Publicado: (2014)

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Recent Advances in the Discovery of Novel Antiprotozoal Agents
por: Lee, Seong-Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j05hvokoh6kg90heh91mlstebv